CIBC Private Wealth Group LLC cut its holdings in Xencor Inc (NASDAQ:XNCR) by 6.6% during the third quarter, HoldingsChannel reports. The firm owned 21,063 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the period. CIBC Private Wealth Group LLC’s holdings in Xencor were worth $710,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Crossmark Global Holdings Inc. acquired a new position in Xencor in the third quarter valued at $403,000. Everence Capital Management Inc. acquired a new position in Xencor in the third quarter valued at $291,000. State of Alaska Department of Revenue acquired a new position in Xencor in the third quarter valued at $1,276,000. Royal Bank of Canada increased its stake in Xencor by 42.7% in the second quarter. Royal Bank of Canada now owns 2,004 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 600 shares during the period. Finally, Nuveen Asset Management LLC acquired a new position in Xencor in the second quarter valued at $11,073,000. Institutional investors own 84.10% of the company’s stock.
A number of research analysts have commented on XNCR shares. Wedbush lifted their price objective on shares of Xencor from $43.00 to $54.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. They noted that the move was a valuation call. Nomura reiterated a “sell” rating and set a $21.00 price target on shares of Xencor in a research note on Thursday, August 8th. Guggenheim lowered shares of Xencor from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Mizuho reiterated a “buy” rating and set a $52.00 price target on shares of Xencor in a research note on Monday, July 1st. Finally, Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research note on Saturday, October 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. Xencor presently has an average rating of “Buy” and a consensus target price of $44.62.
Shares of Xencor stock opened at $36.39 on Wednesday. Xencor Inc has a 52-week low of $27.75 and a 52-week high of $46.33. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.02. The company’s 50-day simple moving average is $35.34 and its 200-day simple moving average is $36.35. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -27.78 and a beta of 1.37.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Xencor had a net margin of 28.46% and a return on equity of 8.40%. The business had revenue of $19.49 million for the quarter, compared to analyst estimates of $7.58 million. Equities research analysts anticipate that Xencor Inc will post 0.05 EPS for the current year.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.